2025 年第 10 期 第 20 卷

不同铂类化疗方案联合斯鲁利单抗一线治疗广泛期小细胞肺癌的临床效果及安全性研究

Study on the clinical efficacy and safety of different platinum-based chemotherapy regimens combined with slulizumab as first-line treatment for extensive-stage small cell lung cancer

作者：席元晟陈岩罗鑫婷杨飞虎王红兵

英文作者：Xi Yuansheng Chen Yan Luo Xinting Yang Feihu Wang Hongbing

单位：徐州医科大学附属医院肿瘤科，徐州221000

英文单位：Department of Oncology the Affiliated Hospital of Xuzhou Medical University Xuzhou 221000 China

关键词：广泛期小细胞肺癌；洛铂；卡铂；斯鲁利单抗；临床疗效

英文关键词：Extensive-stagesmallcelllungcancer;Lobaplatin;Carboplatin;Slulizumab;Clinicalefficacy

• 摘要：

• 目的 研究不同铂类化疗方案联合斯鲁利单抗一线治疗广泛期小细胞肺癌（ES-SCLC）的临床效果和安全性。方法 回顾性选取2022年10月1日至2024年9月30日徐州医科大学附属医院收治的118例ES-SCLC患者。根据化疗方案的不同分为洛铂组（65例）和卡铂组（53例）。洛铂组患者给予洛铂联合依托泊苷和斯鲁利单抗治疗，卡铂组患者给予卡铂联合依托泊苷和斯鲁利单抗治疗，每21天为1个周期，2组患者均治疗4个周期。比较2组患者的一般资料、近期疗效、远期疗效、不良反应发生情况。结果 2组患者性别、年龄、吸烟史、美国东部肿瘤协作组体能状态量表评分、肝转移、脑转移、骨转移、肾上腺转移、胸部放疗的比例比较，差异均无统计学意义（均P＞0.05）。洛铂组和卡铂组客观有效率和疾病控制率比较［64.6%（42/65）比69.8%（37/53），83.1%（54/65）比88.7%（47/53）］，差异均无统计学意义（χ2=0.356，P=0.551； χ2=0.743，P=0.389）。2组患者无进展生存期和总生存期比较，差异均无统计学意义（均P＞0.05）。洛铂组的恶心呕吐和过敏反应发生率均低于卡铂组，差异均有统计学意义（均P＜0.05）。结论 洛铂联合依托泊苷和斯鲁利单抗、卡铂联合依托泊苷和斯鲁利单抗一线治疗ES-SCLC均有良好的效果，洛铂组的恶心呕吐和过敏反应发生率更低，优于卡铂组。

• Objective To investigate the clinical efficacy and safety of different platinum-based chemotherapy regimens combined with slulizumab as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Methods A total of 118 patients with ES-SCLC admitted to the Affiliated Hospital of Xuzhou Medical University from October 1, 2022 to September 30, 2024 were retrospectively selected. According to the different chemotherapy regimens, they were divided into lobaplatin group (65 cases) and carboplatin group (53 cases). The patients in the lobaplatin group were treated with lobaplatin combined with etoposide and slulizumab, and the patients in the carboplatin group were treated with carboplatin combined with etoposide and slulizumab, every 21 days as a cycle. The patients in the two groups were treated for 4 cycles. The general data, short-term efficacy, long-term efficacy, and adverse reactions of the two groups were compared. Results There were no significant differences in gender, age, smoking history, Eastern Cooperative Oncology Group performance status scale score, liver metastasis, brain metastasis, bone metastasis, adrenal metastasis, and thoracic radiotherapy between the two groups (all P＞0.05). There was no significant difference in objective  response rate and disease control rate between lobaplatin group and carboplatin group ［64.6%(42/65) vs 69.8%(37/53), 83.1%(54/65) vs 88.7%(47/53)］(χ2=0.356, P=0.551;χ2=0.743, P=0.389). There were no significant differences in progression-free survival and overall survival between the two groups (both P＞0.05). The incidences of nausea and vomiting and allergic reactions in the lobaplatin group were lower than those in the carboplatin group (both P＜0.05). Conclusion Lobaplatin combined with etoposide and slulizumab and carboplatin combined with etoposide and slulizumab are effective in the first-line treatment of ES-SCLC. The incidence of nausea and vomiting and allergic reactions in the lobaplatin group is lower than that in the carboplatin group.